# Taigen Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/taigen-biotechnology

- Industry: Biotechnology
- Headquarters: Taipei, Taiwan - China
- Website: www.taigenbiotech.com.tw
- Total disclosed funding: $75M
- Latest round: Series C (Jan 20, 2009)
- Investors on record: 5

## About

Based in Taipei, China, and founded in 2001, Taigen Biotechnology operates as a research-based and product-driven pharmaceutical company, dedicated to the development of anti-infective drugs. The company has set up a branch office in Beijing. There are 70 employees in the company, and 80% of them are the research and development staff. The CEO, Guolong Huang, worked at Sandoz, Novartis AG. In July 2001, it raised strategic investment from a new investor National Development Fund of the Executive Yuan. In January 2009, Taigen Biotechnology raised USD 37 million in series C funding led by returning investor MPM Capital with participation from new investor Taiwan Sugar Corporation and returning investor YFY Global Investment (BVI).

The company specializes in the development of drugs for anti-infective diseases. Its main products are TG-1000, Burixafor, NEMONOXACIN, and Flarevir. NEMONOXACIN is effective against drug-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Staphylococcus aureus (VRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and AB bacteria. Furaprevir can work against 6 genotypes of the hepatitis C virus. The drugs can be used in the treatment of liver disease, infectious diseases, and tumors.

## Funding rounds

- Series C, Jan 20, 2009, $37M — YFY Global Investment, MPM BioImpact, Taiwan Sugar Corporation
- Series B, Mar 16, 2004, $38M — CDIB Capital Group, YFY Global Investment, GAINS Investment Corporation, MPM BioImpact

## Investors

- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series B
- YFY Global Investment — Series B, Series C
- GAINS Investment Corporation (https://capitalatlas.ai/funds/gains-investment-corporation) — Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- Taiwan Sugar Corporation — Series C